In this issue:
Biologic therapy and laboratory indicators of cardiometabolic diseases
Paediatric risk of infection with ustekinumab, etanercept, or methotrexate
IL-17 and IL-23 inhibitors in Swedish clinical practice
IL-17 inhibitors in psoriasis
Spesolimab for generalised pustular psoriasis
Dupilumab in adults with atopic dermatitis
Cardiovascular risk in hidradenitis suppurativa treated with adalimumab
Omalizumab in combination with any other biologics
Lebrikizumab for moderate-to-severe atopic dermatitis
Dupilumab for erythrodermic atopic dermatitis
Please login below to download this issue (PDF)